Cardiovascular pharmaceutical composition and its preparation method and application

A combined tablet and prescription technology, applied in the field of medicine, can solve the problems of patient death, high disability rate, and critical hazards

Active Publication Date: 2015-09-09
江苏海悦康医药科技有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the anticoagulant effect of ticagrelor focuses on cardiovascular aspects, and cardiovascular and cerebrovascular diseases often accompany each other. The vast majority of patients with coronary artery sclerosis often have cerebral arteriosclerosis; Cardiovascular and cerebrovascular diseases are usually critical and harmful diseases, and the death and disability rate of patients caused by cardiovascular and cerebrovascular accidents is very high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cardiovascular pharmaceutical composition and its preparation method and application
  • Cardiovascular pharmaceutical composition and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1. Combination tablet of ticagrelor and troxerutin and its preparation

[0044] prescription:

[0045] Ticagrelor 90g

[0046] Troxerutin 150g

[0047] Mannitol 180g

[0048] Calcium hydrogen phosphate 85g

[0049] Sodium carboxymethyl starch 18g

[0050] 2.5% hydroxypropyl cellulose aqueous solution appropriate amount

[0051] Magnesium Stearate 5g

[0052] Preparation method 1: Pass ticagrelor, troxerutin, mannitol, calcium hydrogen phosphate, and sodium carboxymethyl starch through a 100-mesh sieve respectively. After weighing according to the prescription amount, firstly mix ticagrelor and troxerutin uniformly by equal amount addition method to obtain A mixed powder, set aside, and add carboxymethyl starch sodium and calcium hydrogen phosphate by equal amount addition method Mix evenly, then mix evenly with mannitol to get B mixed powder, then mix A mixed powder and B mixed powder evenly, add 2.5% hydroxypropy...

Embodiment 2

[0054] Example 2. Combination tablet of ticagrelor and cinnarizine and its preparation

[0055] prescription:

[0056] Ticagrelor 90g

[0057] Cinnarizine 50g

[0058] Mannitol 160g

[0059] Calcium hydrogen phosphate 85g

[0060] Sodium carboxymethyl starch 18g

[0061] 2.5% hydroxypropyl cellulose aqueous solution appropriate amount

[0062] Magnesium Stearate 5g

[0063] Preparation method 1: Pass ticagrelor, cinnarizine, mannitol, calcium hydrogen phosphate, and sodium carboxymethyl starch through a 100-mesh sieve respectively. After weighing according to the prescription amount, firstly mix ticagrelor and cinnarizine uniformly by equal increment method to obtain A mixed powder, and set aside, then mix sodium carboxymethyl starch and calcium hydrogen phosphate by equal increment method Uniformly, then mix with mannitol evenly to get B mixed powder, then mix A mixed powder and B mixed powder evenly, add 2.5% hydroxypropyl cellu...

Embodiment 3

[0065] Example 3. Combination tablet of ticagrelor and flunarizine hydrochloride and its preparation

[0066] prescription:

[0067] Ticagrelor 90g

[0068] Flunarizine Hydrochloride 10g

[0069] Mannitol 110g

[0070] Calcium hydrogen phosphate 85g

[0071] Sodium carboxymethyl starch 15g

[0072] 2.5% hydroxypropyl cellulose aqueous solution appropriate amount

[0073] Magnesium Stearate 5g

[0074] Preparation method 1: Pass ticagrelor, flunarizine hydrochloride, mannitol, calcium hydrogen phosphate, and sodium carboxymethyl starch through a 100-mesh sieve respectively. After weighing according to the prescription amount, firstly mix ticagrelor and flunarizine hydrochloride uniformly by equal amount addition method to obtain A mixed powder, and set aside, add carboxymethyl starch sodium and calcium hydrogen phosphate by equal amount Add and mix evenly, then mix evenly with mannitol to obtain B mixed powder, then mix A mixed p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition of ticagrelor and a type II therapeutic agent and a preparation method of the pharmaceutical composition. The pharmaceutical composition is characterized in that the type II therapeutic agent is selected from one or more of troxerutin, cinnarizine, flunarizine hydrochloride, ligustrazine, ligustrazine phosphate, sodium ferulate or piperazine ferulate. The invention also relates to application of the pharmaceutical composition in drugs, in particular the application in inhibiting or reversing of atherosclerosis lipid plaques of artery blood vessel.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a pharmaceutical composition for treatment or prevention, which contains ticagrelor and another type of therapeutic agent, and is used for the prevention and treatment of heart, brain and blood vessel diseases, as well as its preparation method and its use in medicine Applications. Background technique [0002] Cardiovascular, cerebrovascular and vascular diseases are diseases with high morbidity, great harm, death, and high disability rate. Cardiovascular and cerebrovascular diseases are essentially vascular lesions, and the main cause of vascular lesions is atherosclerotic plaque in arteries And vascular abnormalities caused by atheromatous lipid plaques, which are the main causes of heart and cerebral ischemia and infarction; about the mechanism of atherosclerosis, there are lipid infiltration, smooth muscle hyperplasia, thrombosis, platelet aggregation and arterial intima inj...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/519A61K31/7048A61P9/10A61P7/02A61P9/00A61K31/495A61K31/192A61K31/4965
Inventor 张耿元王保红白东跃
Owner 江苏海悦康医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap